Health Care [ 4/12 ] | Health Care Equipment & Supplies [ 43/72 ]
NASDAQ | Common Stock
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy.
The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.
It markets its products through a single direct sales force, principally in the United States.
TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.23 Increased by +63.49% | -0.50 Increased by +54.00% |
| Mar 21, 24 | -0.53 Decreased by -1.92% | -0.43 Decreased by -23.26% |
| Nov 9, 23 | -0.45 Increased by +29.69% | -0.49 Increased by +8.16% |
| Aug 9, 23 | -0.46 Increased by +41.77% | -0.53 Increased by +13.21% |
| May 11, 23 | -0.63 Increased by +16.00% | -0.56 Decreased by -12.50% |
| Mar 21, 23 | -0.52 Increased by +11.86% | -0.55 Increased by +5.45% |
| Nov 9, 22 | -0.64 Decreased by -12.28% | -0.63 Decreased by -1.59% |
| Aug 10, 22 | -0.79 Decreased by -38.60% | -0.62 Decreased by -27.42% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 15.05 M Increased by +34.89% | -10.96 M Increased by +8.24% | Decreased by -72.79% Increased by +31.97% |
| Jun 30, 23 | 14.49 M Increased by +39.29% | -10.79 M Increased by +19.16% | Decreased by -74.44% Increased by +41.96% |
| Mar 31, 23 | 11.91 M Increased by +44.68% | -14.05 M Decreased by -18.23% | Decreased by -117.94% Increased by +18.28% |
| Dec 31, 22 | 11.62 M Increased by +38.79% | -9.77 M Decreased by -13.38% | Decreased by -84.08% Increased by +18.31% |
| Sep 30, 22 | 11.16 M Increased by +45.79% | -11.94 M Decreased by -44.46% | Decreased by -107.01% Increased by +0.91% |
| Jun 30, 22 | 10.41 M Increased by +37.68% | -13.35 M Decreased by -61.70% | Decreased by -128.27% Decreased by -17.44% |
| Mar 31, 22 | 8.23 M Increased by +40.05% | -11.88 M Decreased by -46.02% | Decreased by -144.33% Decreased by -4.26% |
| Dec 31, 21 | 8.37 M Increased by +47.77% | -8.62 M Decreased by -10.64% | Decreased by -102.93% Increased by +25.12% |